Hepatocyte transduction via adeno-associated virus vector

“Hepatocyte transduction via adeno-associated virus vector” refers to the process of delivering genetic material to liver cells using engineered AAV viral vectors. This is a widely used research and clinical strategy for liver-directed gene therapy, capitalizing on the high efficiency and stability of AAV-mediated gene transfer to hepatocytes. Various AAV serotypes (such as AAV7, AAV8, AAV5) display differences in efficiency and cell specificity based on their capsid properties and interaction with hepatocyte surface proteins. This approach is central to gene therapies for inherited liver disorders and is the basis for several investigational and approved therapies in humans. However, it is not itself a specific molecular target, but a gene delivery method involving multiple molecular interactions and is subject to both efficacy challenges (immune responses, species differences) and safety considerations (hepatotoxicity, off-target effects).

Other names

AAV liver transductionAAV hepatocyte transductionAAV-mediated gene delivery to hepatocytes

Exploits the viral vector’s ability to enter and deliver DNA to hepatocyte nuclei for long-term gene expression